Childhood pemphigus vulgaris successfully treated with rituximab.

Simple item page
dc.contributor.authorKanwar, Amrinder J
dc.contributor.authorSawatkar, Gitesh U
dc.contributor.authorVinay, Keshavamurthy
dc.contributor.authorHashimoto, Takashi
dc.date.accessioned2012-09-07T09:11:25Z
dc.date.available2012-09-07T09:11:25Z
dc.date.issued2012-09
dc.description.abstractPemphigus is a potentially fatal autoimmune epidermal bullous disorder. Rituximab is a novel therapy for the treatment of refractory pemphigus. However, there is limited clinical data on safety and efficacy of rituximab in pediatric age group. Herein, we report an 11-year-old boy of childhood pemphigus vulgaris who failed to respond to dexamethasone pulse therapy and was subsequently treated with rituximab and achieved complete remission.en_US
dc.identifier.citationKanwar Amrinder J, Sawatkar Gitesh U, Vinay Keshavamurthy, Hashimoto Takashi. Childhood pemphigus vulgaris successfully treated with rituximab. Indian Journal of Dermatology, Venereology and Leprology. 2012 Sept-Oct; 78(5): 632-634.en_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/141179
dc.language.isoenen_US
dc.source.urihttps://www.ijdvl.com/article.asp?issn=0378-6323;year=2012;volume=78;issue=5;spage=632;epage=634;aulast=Kanwaren_US
dc.subjectAutoimmune bullous diseasesen_US
dc.subjectchildhood pemphigus vulgarisen_US
dc.subjectrituximaben_US
dc.titleChildhood pemphigus vulgaris successfully treated with rituximab.en_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
ijdvl2012v78n5p632.pdf
Size:
942.74 KB
Format:
Adobe Portable Document Format
Description:
Journal article
Download
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Indian Journal of Dermatology, Venereology and Leprology